Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Levy

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
The Oncologist|August 16, 2022
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer ImmunotherapyMelinda L Hsu, Joseph C Murray, Kevin J Psoter, et al.
Clinical Lung Cancer|April 30, 2019
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung CancerKhinh Ranh Voong, Sarah Z Hazell, Wei Fu, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
Cancer Research Communications|February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLCMari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint ImmunotherapyKarthik Suresh, Kevin J Psoter, Khinh Ranh Voong, et al.
JTO Clinical and Research Reports|November 8, 2021
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLCJoshua E Reuss, Emily Brigham, Kevin J Psoter, et al.
The Oncologist|September 5, 2024
Proceedings of the 1st biannual bridging the gaps in lung cancer conferenceNarjust Florez, Sandip P Patel, Heather Wakelee, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
The Oncologist|August 16, 2022
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer ImmunotherapyMelinda L Hsu, Joseph C Murray, Kevin J Psoter, et al.
Clinical Lung Cancer|April 30, 2019
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung CancerKhinh Ranh Voong, Sarah Z Hazell, Wei Fu, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
Cancer Research Communications|February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLCMari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint ImmunotherapyKarthik Suresh, Kevin J Psoter, Khinh Ranh Voong, et al.
JTO Clinical and Research Reports|November 8, 2021
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLCJoshua E Reuss, Emily Brigham, Kevin J Psoter, et al.
The Oncologist|September 5, 2024
Proceedings of the 1st biannual bridging the gaps in lung cancer conferenceNarjust Florez, Sandip P Patel, Heather Wakelee, et al.
Pageof 8